Soni Pankaj, Matoria Ramswaroop, Nagalli Manjunath Mallikarjuna
Department of Neonatology, Thumbay University Hospital, Ajman, UAE.
Department of Clinical Sciences (Pediatric Neonatology), College of Medicine, Gulf Medical University, Ajman, UAE.
Eur J Pediatr. 2025 Jun 24;184(7):439. doi: 10.1007/s00431-025-06271-w.
Neonatal sepsis is a critical global health challenge, resulting in high morbidity and mortality. This systematic review and meta-analysis was designed to evaluate the effectiveness of different treatments with antibiotics on neonatal sepsis, as well as resistance patterns affecting treatment outcomes. PubMed, Scopus, and Web of Science articles from January 2005 to December 2024 were included in the analysis. Studies focused on mortality, treatment failure rates, and pathogen-specific resistance profiles. The review involved data from 37 articles, which included 8954 neonates. Findings were that overall mortality rates associated with neonatal sepsis were between 10 and 30% based on the used antibiotic regimen. Combination therapies have modest survival advantage over single agent therapies. Of grave concern in the resistance trends were the incidence of 20% to 45% among aminoglycoside resistance and that of 15% to 35% to third-generation cephalosporins. Carbapenem-resistant Gram-negative pathogens emerged in an incidence of 10% from various regions in the world.
The studies underscored the role of antibiotic stewardship programs and local surveillance in tailoring empirical treatment. Results from this meta-analysis suggest that while combination antibiotic therapies can offer slight survival benefits in the treatment of neonatal sepsis, the rapid escalating resistance rates point to the need for robust stewardship and the continuous updating of treatment guidelines based on local microbial patterns. Future studies should focus on new antibiotics and adjunctive treatment methods to reduce treatment failure and combat the rising antibiotic resistance in neonatal intensive care settings.
• Neonatal sepsis remains a significant global health issue, contributing to high morbidity and mortality rates. • The increasing prevalence of multidrug-resistant (MDR) organisms complicates effective antibiotic selection, limiting treatment options.
• This study incorporates data from 37 articles spanning two decades, offering a comprehensive assessment of antibiotic efficacy in neonatal sepsis treatment. • The review highlights specific antibiotic combinations that demonstrate superior outcomes in reducing mortality and treatment failure rates.
新生儿败血症是一项严峻的全球健康挑战,会导致高发病率和死亡率。本系统评价和荟萃分析旨在评估不同抗生素治疗对新生儿败血症的有效性,以及影响治疗结果的耐药模式。分析纳入了2005年1月至2024年12月发表于PubMed、Scopus和Web of Science上的文章。研究聚焦于死亡率、治疗失败率和病原体特异性耐药谱。该评价涉及37篇文章的数据,共8954例新生儿。研究发现,根据所使用的抗生素治疗方案,新生儿败血症的总体死亡率在10%至30%之间。联合治疗比单药治疗有适度的生存优势。耐药趋势中令人严重担忧的是,氨基糖苷类耐药发生率为20%至45%,第三代头孢菌素耐药发生率为15%至35%。全球不同地区碳青霉烯类耐药革兰阴性病原体的出现率为10%。
这些研究强调了抗生素管理计划和局部监测在制定经验性治疗方案中的作用。该荟萃分析的结果表明,虽然联合抗生素治疗在新生儿败血症治疗中可提供轻微的生存益处,但耐药率的迅速上升表明需要强有力的管理,并根据当地微生物模式持续更新治疗指南。未来的研究应聚焦于新型抗生素和辅助治疗方法,以减少治疗失败,并应对新生儿重症监护环境中不断上升的抗生素耐药性。
• 新生儿败血症仍然是一个重大的全球健康问题,导致高发病率和死亡率。• 多重耐药(MDR)微生物的日益流行使有效的抗生素选择变得复杂,限制了治疗选择。
• 本研究纳入了跨越二十年的37篇文章的数据,全面评估了抗生素在新生儿败血症治疗中的疗效。• 该评价突出了在降低死亡率和治疗失败率方面显示出更好结果的特定抗生素联合用药。